- Home
- CADL vs JGH Comparison
CADL vs JGH Comparison
Compare CADL & JGH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CADL | JGH |
|---|---|---|
| Founded | 1999 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 339.8M | 292.3M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | CADL | JGH |
|---|---|---|
| Price | $6.01 | $12.57 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $19.43 | N/A |
| AVG Volume (30 Days) | ★ 979.3K | 73.9K |
| Earning Date | 11-13-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.85% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.25 | $10.36 |
| 52 Week High | $13.68 | $12.85 |
Technical Indicators
Market Signals| Indicator | CADL | JGH |
|---|---|---|
| Relative Strength Index (RSI) | 60.31 | 52.42 |
| Support Level | $5.45 | $12.39 |
| Resistance Level | $6.14 | $12.50 |
| Average True Range (ATR) | 0.41 | 0.08 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 43.40 | 75.99 |
Price Performance
Historical ComparisonAbout CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
About JGH Nuveen Global High Income Fund of Beneficial Interest
Nuveen Global High Income Fund operates as a diversified closed-end management investment company. The fund's investment objective is to provide a high level of current income. Its securities include U.S. high-yield bonds; non-U.S. high-yield bonds from developed and emerging markets; and other income-producing investments such as preferred and convertible securities.